Clinical trial
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
NCT00478452 · University of Pennsylvania, Other · Completed
Key facts
| NCT number | NCT00478452 |
|---|---|
| Title | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients |
| Official title | Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma |
| Acronym | DC-Ova |
| Lead sponsor | University of Pennsylvania, Other |
| Collaborators | Fox Chase Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma |
| Intervention type | Biological |
| Interventions | DC-Ova, DC Ova with Cyclophosphamide |
| Enrollment | 14 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | May 24, 2007 |
| Last update posted | Oct 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: